Aug 13, 2020
Amgen Announces Early Tender Results Of Senior Notes Exchange Offers
Aug 03, 2020
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
May 08, 2020
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
May 05, 2020
KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer
Mar 31, 2020
Amgen Establishes Wholly-Owned Affiliate In Japan
Feb 26, 2020
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Jan 30, 2020
Amgen Reports Fourth Quarter And Full Year 2019 Financial Results
Jan 25, 2020
The Exceptional Women Awardees Foundation announces that Vanessa Belozeroff, Executive Director, Amgen, joins the EWA January 2020 Cohort of Women Leader Awardees
Oct 29, 2019
Amgen Reports Third Quarter 2019 Financial Results
Jul 30, 2019
Amgen Reports Second Quarter 2019 Financial Results
Jul 26, 2019
Amgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period
Jul 08, 2019
Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer
Jun 12, 2019
Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
May 29, 2019
Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution
May 22, 2019
Statement by the Board of Directors of Nuevolution in Relation to the Public Offer From Amgen
May 22, 2019
Amgen announces a recommended public cash offer to the shareholders of Nuevolution
Apr 30, 2019
Amgen Reports First Quarter 2019 Financial Results
Mar 20, 2019
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Feb 21, 2019
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Jan 29, 2019
Amgen Reports Fourth Quarter And Full Year 2018 Financial Results